Interferon- β inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjögren’s syndrome

ConclusionOur findings highlight a consistent ex vivo inhibitory effect of IFN- β on pro-inflammatory cytokine production and NO pathway in pSS patients. Our data suggest that IFN-β could represent a potential candidate for targeting inflammation during pSS.
Source: Inflammopharmacology - Category: Drugs & Pharmacology Source Type: research